Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Other Operating Expenses (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Other Operating Expenses for 7 consecutive years, with $4.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 26.78% to $4.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.5 million, a 45.8% increase, with the full-year FY2025 number at $19.5 million, up 45.81% from a year prior.
  • Other Operating Expenses was $4.8 million for Q4 2025 at Rhythm Pharmaceuticals, down from $5.5 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $27.8 million in Q3 2021 to a low of $4000.0 in Q1 2021.
  • A 5-year average of $4.4 million and a median of $2.9 million in 2024 define the central range for Other Operating Expenses.
  • Biggest YoY gain for Other Operating Expenses was 5650.0% in 2022; the steepest drop was 98.21% in 2022.
  • Rhythm Pharmaceuticals' Other Operating Expenses stood at $236000.0 in 2021, then surged by 335.59% to $1.0 million in 2022, then soared by 214.49% to $3.2 million in 2023, then grew by 17.14% to $3.8 million in 2024, then rose by 26.78% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Other Operating Expenses are $4.8 million (Q4 2025), $5.5 million (Q3 2025), and $5.5 million (Q2 2025).